- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06184633
NEDERLANDSK vektkontroll i atrieflimmerstudie (DUTCH-WAIST)
NEDERLANDSK vektkontroll i atrieflimmerstudie, en multisenter, dobbeltblind, randomisert, parallell gruppe, placebokontrollert studie
Quantify the effect of an innovative weight loss management on rhythm control.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Rationale: Weight reduction promotes reversed atrial remodeling in obese AF patients.
Objective: Quantify the effect of an innovative weight loss management on rhythm control.
Study design: Multi-center, double-blind, randomized, parallel group, placebo-controlled trial of semaglutide 2.4 mg versus placebo.
Study population: Adults with obesity and new onset persistent AF scheduled for electrical cardioversion.
Intervention: semaglutide 2.4 mg subcutaneous (s.c.) once weekly (index) compared to placebo (control), at the background of standard obesity treatment (combined lifestyle intervention) and cardiology follow-up management in both arms.
Main study parameters/endpoints: The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome. The 7 mutually exclusive outcomes hierarchically ranked from worst to best are:
-
Arrhythmic death while using anti-arrhythmic drugs (Vaughn-Williams class I or III)*
-
AF despite pulmonary vein isolation
-
AF despite current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
AF without a pulmonary vein isolation and without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
Sinus rhythm on the 12-lead ECG with the use of a pulmonary vein isolation
-
Sinus rhythm on the 12-lead ECG with current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
Sinus rhythm on the 12-lead ECG without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III) and without a pulmonary vein isolation
- When LTFU or death other than anti-arrhythmic death, last known rhythm will be used.
Studietype
Registrering (Antatt)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
's-Hertogenbosch, Nederland
- Jeroen Bosch Ziekenhuis
-
Alkmaar, Nederland
- Noordwest Ziekenhuisgroep
-
Amsterdam, Nederland
- Amsterdam UMC
-
Breda, Nederland
- Amphia Ziekenhuis
-
Deventer, Nederland
- Deventer Ziekenhuis
-
Doetinchem, Nederland
- Slingeland Ziekenhuis
-
Eindhoven, Nederland
- Máxima MC
-
Emmen, Nederland
- Treant Zorggroep
-
Goes, Nederland
- Admiraal de Ruyter Ziekenhuis
-
Groningen, Nederland
- Martini Ziekenhuis
-
Groningen, Nederland
- Universitair Medisch Centrum Groningen
-
Haarlem, Nederland
- Spaarne Gasthuis
-
Heerlen, Nederland
- Zuyderland Medisch Centrum
-
Leeuwarden, Nederland
- Frisius MC
-
Maastricht, Nederland
- Maastricht UMC+
-
Roosendaal, Nederland
- Bravis ziekenhuis
-
The Hague, Nederland
- HagaZiekenhuis
-
The Hague, Nederland
- Haaglanden Medisch Centrum
-
Utrecht, Nederland
- Diakonessenhuis
-
-
Gelderland
-
Arnhem, Gelderland, Nederland
- Rijnstate Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Symptomatic, first detected (at maximum 6 months prior to enrollment) persistent AF -
-
Age ≥ 18
-
Obesity, as defined as:
- BMI ≥ 30 kg/m2, or
- BMI ≥27 kg/m2 with the presence of at least one weight related comorbidity (treated or untreated, e.g. hypertension, dyslipidaemia, obstructive sleep apnea, cardiovascular disease)
-
Scheduled ECV
-
Written informed consent
Exclusion Criteria:
- Permanent AF
- Secondary AF, i.e. due to thyrotoxicosis, infection (e.g. pneumonia) or post-(cardiothoracic) surgery
- Current or previous treatment with amiodaron
- HbA1c ≥ 48 mmol/mol, <3 months prior to randomization
- History of diabetes mellitus type 1 or 2
- Prior bariatric surgery
- Use of other anti-obesity medication, <3 months prior to enrollment
- Contra-indication for, or prior use of a GLP1-receptor agonist
- History of chronic pancreatitis or acute pancreatitis <6 months
- Acute coronary syndrome <6 months
- Severe (grade III) valvular disease
- eGFR <30 mL/min/1.73m2
- Heart failure NYHA class III-IV
- Participation in another investigational drug or device study in the past 30 days (registry enrollment is allowed)
- Any condition or therapy, which would make the participant unsuitable for the study (e.g. vulnerable, non-compliance) or life-expectancy <12 months, as judged by the treating physician.
- Female who is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Intervention
Semaglutide injections + combined lifestyle intervention |
Intervention arm receives semaglutide in addition to combined lifestyle intervention |
|
Placebo komparator: Placebo
Placebo Semaglutide injections + combined lifestyle intervention |
Control arm receives placebo in addition to combined lifestyle intervention |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome
Tidsramme: At 1 year follow-up
|
The 7 mutually exclusive outcomes hierarchically ranked from worst to best are:
|
At 1 year follow-up
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antall sykehusinnleggelser på grunn av tilbakefall av AF.
Tidsramme: uke 0-52
|
uke 0-52
|
|
|
Antall ikke-planlagte sykehusbesøk på grunn av uønskede hendelser av AAD.
Tidsramme: uke 0-52
|
uke 0-52
|
|
|
Antall planlagte elektriske elkonverteringer.
Tidsramme: uke 0-52
|
uke 0-52
|
|
|
Antall uplanlagte elektriske kardioversjoner.
Tidsramme: uke 0-52
|
uke 0-52
|
|
|
Antall intravenøse kjemiske kardioversjoner (ved bruk av Vaughan-Williams klasse I legemidler).
Tidsramme: uke 0-52
|
uke 0-52
|
|
|
Totalt antall uplanlagte kardioversjoner.
Tidsramme: uke 0-52
|
uke 0-52
|
|
|
Endring i midjeomkrets, målt i cm
Tidsramme: uke 0 og 52
|
uke 0 og 52
|
|
|
Vektendring, målt i % og kg
Tidsramme: uke 0 og 52
|
uke 0 og 52
|
|
|
Endring i BMI, målt i kg/m2
Tidsramme: uke 0 og 52
|
uke 0 og 52
|
|
|
Change in AF related symptoms measured by the modified EHRA classification between the index visit and at 12 months after the index visit.
Tidsramme: week 0 and 52
|
EHRA: European Heart Rythm Association 1= no symptoms 2a= mild symptoms; Normal dialy activity not affected, symptoms not troublesome to patient 2b= moderate symptoms; Normal daily activity not affected but patient troubled by symptoms 3= severe symptoms; Normal daily activity affected 4= disabling symptoms; Normal daily activity discontinued |
week 0 and 52
|
|
Change in quality of life measured by the EQ-5D-5L between the index visit and at 12 months after the index visit.
Tidsramme: week 0 and 52
|
Descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), each of which has five severity levels that are described by statements appropriate to that dimension. LEVEL 1: indicating no problem LEVEL 2: indicating slight problems LEVEL 3: indicating moderate problems LEVEL 4: indicating severe problems LEVEL 5: indicating unable to/extreme problems |
week 0 and 52
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ron Pisters, dr., Rijnstate Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Ernæringsforstyrrelser
- Hjertesykdommer
- Overernæring
- Kroppsvekt
- Endringer i kroppsvekt
- Arytmier, hjerte
- Overvektig
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Tegn og symptomer
- Overvekt
- Vekttap
- Atrieflimmer
- semaglutid
Andre studie-ID-numre
- U1111-1275-9989
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .